CHD

Business profile & competitive position

Church & Dwight Co., Inc. (NYSE: CHD) sits in the Consumer Defensive sector, specifically the Household & Personal Products industry. The company’s business is built around branded household and personal care staples—think laundry additives, baking soda, cat litter, oral care, contraceptives, and pregnancy tests sold under names like Arm & Hammer, OxiClean, Trojan, and First Response. Because these are repeat-purchase, everyday products, demand is relatively stable over an economic cycle, which is exactly the profile implied by CHD’s 0.47 beta.

The latest financial signature is instructive: a 12.0% net margin and a 17.8% return on equity, with a market price of $103.51 as of the 2026-08-10 snapshot. A 12.0% net margin says the company retains meaningful value after cost of goods and operating expenses, while a 17.8% ROE suggests it is generating solid returns on the book equity it deploys. In household and personal products, where shelf-space negotiations, brand trust, and pricing power matter, those figures point to a real but finite competitive moat. The moat is not necessarily insurmountable; private-label competition and input-cost swings can pressure both margins and ROE. Still, the combination of low beta, steady margins, and above-average ROE supports the interpretation that CHD is perceived as a defensive quality asset rather than a cyclical growth story.

Financial posture

With a $24.5 billion market capitalization and a 33.2 P/E, CHD carries a meaningful valuation premium. The stock is quoted at $103.51, sitting above its 50-day exponential moving average of $98.42 and registering an RSI of 63.3. That technical snapshot suggests recent relative strength without the stock being deeply overbought.

The 33.2 P/E is the key valuation anchor. It towers above the multiple typically associated with slow-growth consumer staples, which tells you that investors are paying up for earnings stability, low volatility, and consistent execution. The 12.0% net margin and 17.8% ROE provide a profitability foundation that can justify part of that premium, but a P/E above 30 also leaves limited room for operational disappointment. The 0.47 beta reinforces why such valuations can persist: in volatile markets, a low-beta defensive cash-flow stream is frequently rerated higher. In short, CHD is priced as a premium-quality defensive name whose multiple relies on continued margin and return discipline.

Macro & geopolitical exposure

Because CHD is classified as Consumer Defensive / Household & Personal Products, its macro exposure is less about recession-induced demand collapse and more about input-cost pressure and consumer trade-down. The industry is exposed to commodity chemicals, soda ash, paper and pulp, plastics and resins, packaging materials, freight and transportation fuel costs, and labor inflation. Any sustained rise in those inputs compresses gross margins unless the company can pass price increases through to retailers and consumers.

Currency translation is another factor: staples companies with international revenue face euro, pound, peso, and emerging-market FX impacts on reported results. Trade policy matters too, since tariffs on imported chemicals, packaging, or finished goods can raise unit costs or disrupt supply chains. Regulatory risk is also inherent to the industry: products such as oral care, contraceptives, pregnancy tests, deodorants, and laundry additives are subject to FDA, EPA, CPSC, and FTC oversight around labeling, safety, and advertising claims. Finally, private-label competition from retailers can pressure volume and pricing during periods of consumer stress. So while CHD is defensive in terms of demand, it is not immune to margin, trade, currency, or regulatory headwinds.

Recent developments

The most recent headline flow is dominated by the company’s second-quarter 2026 report. On 2026-07-31, SeekingAlpha.com published the Q2 2026 earnings call transcript, while GuruFocus.com highlighted a 5.8% organic sales surge and a raised full-year outlook. MarketBeat.com also covered the Q2 earnings call highlights the same day. The reported EPS for that quarter was $0.89, just below the $0.896 estimate, producing a -0.7% surprise. Yet the organic sales acceleration and improved guidance appeared to frame the quarter as better than the narrow EPS miss suggested.

On 2026-08-07, DefenseWorld.net ran a head-to-head review comparing Church & Dwight and Reynolds Consumer Products (NASDAQ: REYN), underscoring investor interest in how CHD stacks up against another consumer staples peer. The stock’s most recent price action—$103.51 with a 50-day EMA of $98.42—reflects a market that has largely absorbed the Q2 report and is now looking toward the next release.

Earnings behavior & post-earnings drift

CHD’s earnings track record over the last eight reported quarters is 6 beats out of 8, a 75% beat rate, with an average earnings surprise of 5.2%. The average five-day price move following those reports is +1.32%, classified as an upward drift. At first glance, that looks like the typical “beat-and-rally” pattern investors expect from a defensive staples name.

The last four quarters, however, reveal a more complicated relationship between surprises and post-earnings drift. On 2025-10-31, CHD delivered a 10.1% beat with actual EPS of $0.81 against a $0.736 estimate, yet the stock fell 1.61% the next day and 0.95% over the following five days. On 2026-05-01, the company beat by 2.0% with $0.95 versus $0.931, and the reaction was even more negative: -3.26% the next day and -2.69% over five sessions. In contrast, the most recent quarter—2026-07-31—was a -0.7% miss with $0.89 versus $0.896, yet the stock rose 1.21% the next day and 4.48% over the next five days. The only beat in this four-quarter window that produced a clear positive drift was 2026-01-30: a 2.9% beat with $0.86 versus $0.836, followed by a 1.13% next-day gain and a 4.45% five-day gain.

That disconnect is the most important earnings behavior insight. The market’s real expectation is evidently not captured by EPS alone; guidance revisions, organic sales momentum, margin commentary, and category-specific commentary appear to drive the post-release drift. A strong beat can be sold if forward commentary is soft, while a modest miss can rally if full-year guidance is raised and top-line trends look healthy. With the next report scheduled for 2026-10-30 before the open and a current consensus EPS estimate of $0.90, traders and analysts will likely focus at least as much on organic sales trajectory and management’s updated full-year outlook as on the bottom-line number itself.

For readers who want to go further, the full institutional verdict—covering sell-side rating distributions, target price dispersion, and evolving estimate revisions—offers the next logical layer of context beyond the raw earnings pattern.